Scopolamine - Georgetown Translational Pharmaceuticals

Drug Profile

Scopolamine - Georgetown Translational Pharmaceuticals

Alternative Names: GTP-011; Repurposed scopolamine - GTP; Scopolamine - GTP

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Georgetown Translational Pharmaceuticals
  • Class Antiemetics; Antispasmodics; Hypnosedatives; Mydriatics; Small molecules; Tropanes
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Motion sickness

Most Recent Events

  • 17 Aug 2017 Chemical structure information added
  • 08 Aug 2017 Georgetown Translational Pharmaceuticals announces intention to submit an IND application to US FDA for Motion sickness in the last quarter of 2017
  • 08 Aug 2017 Georgetown Translational Pharmaceuticals plans a phase I proof-of-concept trial in Healthy volunteers in unknown countries in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top